Mehabe score: 6 G Factor: 4 Piotski Score: 5 The stock has a rating HOLD. The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 4 and Piotski score of 5.
Description
Tejnaksh Healthcare is engaged in the provision hospital and healthcare service.Site:539428Main Symbol:TEJNAKSH
Stock trades at 119.0, above its 50dma 88.03. It also trades above its 200dma 72.41. The stock remains bullish on techicals
The 52 week high is at 110.00 and the 52week low is at 22.95
Price Chart
P/E Chart
Sales and Margin
Strengths
– has reduced debt.
Weakness
– Though the company is reporting repeated profits, it is not paying out dividend
Competition
– The industry trades at a mean P/E of 38.4x. Max Healthcare trades at the industry’s max P/E of 236.78x. 539428 trades at a P/E of 44.1x
– Industry’s mean G-Factor is 3.9 while the mean Piotski score is 9.0. 539428 has a G-Factor of 4 and Piotski scoreof 5.
– Average 1 month return for industry is 3.1%. The max 1- month return was given by Metropolis Healt: a return of 14.22 %
Quarterly Results
Sales for period ended Jun 2021 is Rs 3.21 cr compared to Rs 1.58 cr for period ended Jun 2020, a rise of 103.2%
Operating Profits reported at Rs 1.21 cr for period ended Jun 2021 vis-vis 0.38 for period ended Jun 2020 .
Operating Margins expanded 1364.4 bps for period ended Jun 2021 vis-vis Jun 2020 .
The EPS for Jun 2021 was Rs 0.75 compared to Rs 0.78 for previous quarter ended Mar 2021 and Rs 0.07 for Jun 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 13.58 cr for period ended TTM vis-vis sales of Rs 11.96 cr for the period ended Mar 2021, a healthy growth of 11.9%. The 3 year sales cagr stood at -11.8%.
Operating margins expanded to 33.36% for period ended TTM vis-vis 31.1% for period ended Mar 2021, expansion of 226.0 bps.
Net Profit reported at Rs 2.74 cr for period ended TTM vis-vis sales of Rs 2.05 cr for the period ended Mar 2021, rising 25.2%.
Company reported a poor Net Profit CAGR of -3.3% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
CashFlow from operating activities: Rs 1.18 cr for period ended Mar 2021 vis-vis Rs 1.16 cr for period ended Mar 2020
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has worsened on its Return on Equity (RoE) metric. The RoE on Last Year basis was 13.0% compared to 17.0% over the last 3 Years. – The stock has given a return of 201% on a 1 Year basis vis-vis a return of 24% over the last 3 Years. – The compounded sales growth on a TTM bassis is -2% vis-vis a compounded sales growth of -5% over the last 3 Years. – The compounded profit growth on a TTM basis is 94% vis-vis a compounded profit growth of -11% over the last 3 Years.
Ratios
Shareholding Pattern
– Public shareholding has remained largely constant. The Sep 2021 public holding stood at 26.16% vis-vis 26.15% for Jun 2021
Conclusion
– has reduced debt. – Though the company is reporting repeated profits, it is not paying out dividend
The business fundamentals of the stock remain stable. Stronger near term results will build interest in the stock. We suggest to wait for a upturn in business performance.
Technically, the stock remains above its 50 DMA 88.03 and is trading at 119.0, thus bullish price action wise.
